By Andrew Baum, Financial Times
Even with a US Democratic administration that holds control of both the House of Representatives and the Senate, the majority of healthcare investors seem largely unconcerned over the risk to drug pricing.
This may be because the prospect of approval of bills such as HR3, which would give the US government the ability to directly negotiate drug pricing, looks close to zero given how the slim the Democratic majority in the Senate actually is.
